Moderna, Inc. (NASDAQ: MRNA) saw its stock surge 5.79% during intraday trading on Friday, reflecting renewed investor confidence in the biotech company.
The rally follows Moderna's better-than-expected full-year 2025 outlook, with revenue now projected at $1.9 billion, $100 million above the midpoint provided earlier. The company also improved its cost picture, lowering its GAAP operating expense forecast by roughly $200 million and increasing its projected year-end cash balance to $8.1 billion. These positive financial updates have fueled significant optimism among investors.
Additionally, Moderna's Momentum score in Benzinga’s Edge Stock Rankings has surged from 22.5 to 74.61 in just one week, indicating a sharp turnaround in investor sentiment. The stock has gained 76% from its November 2025 lows, with shares climbing 31.7% in the past month and 14.8% over the past week alone.